Renaissance Technologies
IMRX icon

Renaissance Technologies’s Immuneering IMRX Stock Holding History

Renaissance Technologies’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-72,875
Closed -$384K – 3405
2026
Q1 		$384K Sell
72,875
-79,425
-52% -$407K ﹤0.01% 2712
2025
Q4 		$1M Buy
152,300
+117,300
+335% +$753K ﹤0.01% 2276
2025
Q3 		$245K Buy
35,000
+16,800
+92% +$87.2K ﹤0.01% 3079
2025
Q2 		$61.3K Buy
+18,200
New +$31.2K ﹤0.01% 3366
2024
Q3 		– Sell
-349,100
Closed -$447K – 3699
2024
Q2 		$447K Buy
+349,100
New +$574K ﹤0.01% 2746
2022
Q3 		– Sell
-25,537
Closed -$138K – 4210
2022
Q2 		$138K Sell
25,537
-32,063
-56% -$171K ﹤0.01% 3759
2022
Q1 		$373K Buy
+57,600
New +$553K ﹤0.01% 3364

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Renaissance Technologies's IMRX Position: Q2 2026 in Review

Renaissance Technologies sold out of Immuneering (IMRX) in Q2 2026, closing a stake of 72,875 shares — an estimated $384K sold.

Renaissance Technologies first reported a position in IMRX in Q1 2022 and held it in 7 quarters. The position peaked at $1M in Q4 2025. 111 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Renaissance Technologies reported no remaining Immuneering position as of Q2 2026 after selling out during the quarter.
  • Renaissance Technologies sold 72,875 Immuneering shares in Q2 2026, an estimated $384K.
  • Renaissance Technologies first reported a position in Immuneering in Q1 2022 and held it in 7 quarters.
  • Renaissance Technologies's Immuneering position peaked at $1M in Q4 2025.
  • 111 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.